Welcome to our dedicated page for CME Group SEC filings (Ticker: CME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CME Group's 10-K annual reports detail the exchange's complex revenue streams across six asset classes, revealing which derivatives categories drive transaction volumes and how clearing fee structures generate income. The Market Regulation and Risk Management sections explain how the company monitors trading activity and manages counterparty risk through its clearinghouse operations—critical disclosures for understanding the infrastructure supporting global derivatives markets.
Form 10-Q quarterly filings break down trading volumes by product category, showing seasonal patterns in agricultural futures, volatility-driven spikes in equity index contracts, and steady institutional demand for interest rate products. These reports also disclose average revenue per contract, helping investors understand pricing power across different derivatives types. CME Group's segment reporting separates transaction fees, clearing fees, market data revenue, and other income streams, providing transparency into the business model's margin profile.
The company's Form 4 insider transaction filings track when executives and directors buy or sell CME Group shares, offering signals about management confidence in the exchange's competitive position and growth trajectory. Given the company's network effects and dominant market share in key products, insider activity can indicate views on long-term market structure trends. Our AI summaries highlight unusual trading patterns and significant position changes without requiring manual analysis of dozens of individual filings.
Proxy statements (DEF 14A) reveal executive compensation structures tied to trading volume growth, clearing market share, and technology investments. For a business where scale drives profitability, understanding how management incentives align with volume growth versus margin expansion provides insight into strategic priorities. CME Group's 8-K filings announce material events including regulatory approvals for new clearing services, major contract launches, and strategic partnerships that expand the exchange's product ecosystem.
CME Group Inc. reported that its Chairman and CEO Terrence A. Duffy, who is also a director, sold 25,000 shares of Class A common stock on December 11, 2025.
The sale was executed in two trades: 13,809 shares at prices ranging from $268.66 to $269.66 per share and 11,911 shares at prices ranging from $269.68 to $270.51 per share, with prices within each $1 range aggregated and reported on a weighted-average basis. After these transactions, Duffy directly beneficially owned 65,804 Class A shares.
CME Group Inc. officer Derek Louis Sammann, Senior Managing Director and Global Head of Commodities Markets, reported several transactions in CME Class A common stock. On November 6, 2025, he transferred 2,300 shares at a stated price of $0, reducing his direct holdings to 8,683 shares and increasing the holdings of his revocable living trust to 16,914 shares, reflecting an internal ownership reorganization.
On November 20, 2025, the trust sold 5,886 shares at $275.65 per share, leaving the trust with 11,028 shares. On the same date, Sammann’s spouse sold 1,314 shares at $275.74 per share, leaving 7,022 shares held by the spouse. These trades update disclosed indirect ownership positions through both the trust and spouse.
CME Group (CME) insider transaction: Officer Hilda Harris Piell, Sr MD & Chief HR Officer, reported a Code G gift of 973 Class A common shares on 11/07/2025 at a reported price of $0. Following the transaction, she beneficially owns 29,418 shares, held directly.
The filing notes the shares were gifted to her donor advised fund. This is a charitable transfer rather than a market sale.
CME Group Inc. (CME) reported an insider transaction: Director Harold Ford Jr. sold 1,000 Class A shares on November 3, 2025, coded S (open market sale). The weighted average sale price was $263.53, with a price range of $263.21–$263.68.
Following the sale, he directly owns 1,091 shares. The company notes prices within a $1 range were aggregated and maintains detailed records available upon request.
CME Group Inc. reported Q3 2025 results with total revenue of
Market data and information services grew to
Year‑to‑date, operating cash flow reached
CME Group Inc. furnished an 8-K announcing quarterly results. The company reported that a press release dated October 22, 2025, covering financial results for the quarter ended September 30, 2025, was furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition).
The press release includes non-GAAP measures—revenues, expenses, operating income, net income, and earnings per share—with reconciliations to the most comparable GAAP metrics pursuant to Regulation G. The Item 2.02 information, including the exhibit, is furnished and not deemed filed under Section 18 of the Exchange Act.
Jonathan L. Marcus, Senior Managing Director and General Counsel at CME Group Inc. (CME), reported a sale of 392 shares of Class A common stock on 09/18/2025 at a reported price of $262 per share. The filing shows the transaction was executed under a Rule 10b5-1 trading plan adopted on February 18, 2025. After this sale the reporting person beneficially owns 7,851 shares of Class A common stock. The Form 4 is singularly filed for one reporting person and was signed by Margaret Austin Wright on behalf of Jonathan L. Marcus.
Form 144 notice for CME Group Inc. (CME) shows a proposed sale of 392 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $102,704.00 and an approximate sale date of 09/18/2025 on NASDAQ. The securities were acquired from the issuer as restricted stock on 09/16/2025 and payment was recorded as 09/16/2025. The filing also reports prior transactions: the person for whose account the sale is filed sold 376 shares on 09/16/2025 for gross proceeds of $97,368.96. The filing includes the required representation that the signer does not possess undisclosed material adverse information.
Sunil K. Cutinho, Chief Information Officer of CME Group Inc. (CME), reported share transactions on Form 4 tied to restricted stock vesting. On 09/15/2025 he surrendered 1,117 Class A shares at $258.83 per share to satisfy tax withholding and later received 3,044 shares at the same price, leaving him with 19,367 Class A shares after that trade. On 09/16/2025 he surrendered 379 Class A shares at $259.83 for tax withholding, resulting in 18,988 shares held. The filing is signed on behalf of Mr. Cutinho on 09/17/2025 and lists these transactions as related to vesting and tax obligations.
Julie Winkler, Senior Managing Director and Chief Commercial Officer at CME Group (CME), reported insider transactions related to restricted stock vesting and tax-withholding on September 15-16, 2025. On 09/15/2025 she surrendered 1,081 shares at $258.83 to satisfy tax withholding upon vesting and received 3,044 shares at $258.83 from the vesting event, and on 09/16/2025 she surrendered 379 shares at $259.83 for tax withholding. After these transactions she beneficially owned 25,512 Class A shares. The Form 4 was signed on behalf of Ms. Winkler by Margaret Austin Wright on 09/17/2025. The filing shows routine equity vesting and share-withholding to cover taxes; no derivative transactions or additional compensatory arrangements are disclosed in this Form 4.
FAQ
What is the current stock price of CME Group (CME)?
What is the market cap of CME Group (CME)?
